Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 3, 2012, Pages

  Aisen, Paul S ^a   Cummings, Jeffrey ^b   Schneider, Lon S ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AC 1202; ALPHA TOCOPHEROL; APOLIPOPROTEIN E4; CHOLINESTERASE INHIBITOR; CYANOCOBALAMIN; CYTOCHROME P450; DOCOSAHEXAENOIC ACID; DONEPEZIL; ESTROGEN; FLAVONOID; FOLIC ACID; GALANTAMINE; GINKGO BILOBA EXTRACT; GINKGOLIDE A; GINKGOLIDE B; GINKGOLIDE J; HOMOCYSTEINE; HOMOTAURINE; HUPERZINE A; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTROPHIC FACTOR; NUTRACEUTICAL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PYRIDOXINE; RIVASTIGMINE; TACRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN; VITAMIN B GROUP; VIVIMIND; ALKALOID; AMINO ACID; AMPA RECEPTOR; CARBAMIC ACID DERIVATIVE; CEREBROLYSIN; INDAN DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE; PSYCHOTROPIC AGENT; SESQUITERPENE; VITAMIN B COMPLEX;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; COGNITION; COGNITIVE DEFECT; COGNITIVE DEVELOPMENT; DAILY LIFE ACTIVITY; DEMENTIA; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; EPISODIC MEMORY; GENE TARGETING; HUMAN; LEWY BODY; MULTIINFARCT DEMENTIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANIMAL; DISEASE COURSE; DRUG APPROVAL; DRUG EFFECT; GINKGO BILOBA; HALF LIFE TIME; HISTORY; PHYTOTHERAPY; REVIEW;

ALKALOIDS; ALZHEIMER DISEASE; AMINO ACIDS; ANIMALS; CHOLINESTERASE INHIBITORS; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; DOCOSAHEXAENOIC ACIDS; DRUG APPROVAL; GALANTAMINE; GINKGO BILOBA; HALF-LIFE; HISTORY, 20TH CENTURY; HUMANS; INDANS; MEMANTINE; NOOTROPIC AGENTS; PHENYLCARBAMATES; PHYTOTHERAPY; PIPERIDINES; PSYCHOTROPIC DRUGS; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; SESQUITERPENES; VITAMIN B COMPLEX; VITAMIN E;

EID: 84866453747     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a006395     Document Type: Article

References (94)

1. AD2000 Collaborative Group. 2004. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial. Lancet 363: 2105-2115.
2. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, et al. 2000. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 54: 588-593.
3. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, JinS, Thomas RG, Thal LJ. 2003. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. J Am Med Assoc 289: 2819-2826.
4. Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, Garceau D. 2006. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 67: 1757-1763.
5. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, et al. 2008. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: A randomized controlled trial [see comment]. J Am Med Assoc 300: 1774-1783.
6. Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, et al. 2011. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 270-279.
7. Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V, Grigorieva I, Ivanov YU, Sablin S, Zefirov N. 2001. Antihistamine agent dimebon as a novel neuroprotector and a cognition enhancer. Ann NY Acad Sci 939: 425-435.
8. Bakchine S, Loft H. 2008. Memantine treatment in patients with mild to moderate Alzheimer's disease: Results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 13: 97-107.
9. Ballard C, Waite J. 2006. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev CD003476.
10. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill R, Juszczak E, Yu LM, Jacoby R. 2009. The dementia antipsychotic withdrawal trial (DART-AD): Long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 8: 151-157.
11. Birks J. 2006. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev CD005593.
12. Birks J, Grimley Evans J. 2009. Ginkgo biloba for cognitive impairment and dementia. John Wiley, Chichester, UK.
13. Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R. 2003. Efficacy and tolerability of donepezil in vascular dementia: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 34: 2323-2330.
14. Craft S. 2007. Insulin resistance and Alzheimer's disease pathogenesis: Potential mechanisms and implications for treatment. Curr Alzheimer Res 4: 147-152.
15. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, et al. 2011. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment. Arch Neurol doi: 10. 1001/archneurol. 2011. 233.
16. Cummings J. 2003. Neuropsychiatry of Alzheimer's disease and related dementias. Martin Dunitz, London.
17. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, GornbeinJ. 1994. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-2314.
18. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, et al. 2008. Ginkgo biloba for prevention of dementia: A randomized controlled trial. J Am Med Assoc 300: 2253-2262.
19. Dodge HH, Zitzelberger T, Oken BS, Howieson D, Kaye J. 2008. A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology 70: 1809-1817.
20. Doody RS. 2009. Dimebon as a potential therapy for Alzheimer's disease. CNS Spectr 14: 16-18.
21. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D. 2008. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: A randomised, double-blind, placebo-controlled study. Lancet 372: 207-215.
22. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, et al. 2004. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351: 2509-2518.
23. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. 2002. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet 359: 1283-1290.
24. Folstein MF, Folstein SE, McHugh PR. 1975. "Mini-mental state. " A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
25. 2+ in hippocampal slices. Neuropharmacology 38: 1253-1259.
26. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S. 1997. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 (Suppl 2): S33-S39.
27. Gan L. 2007. Therapeutic potential of sirtuin-activating compounds in Alzheimer's disease. Drug News Perspect 20: 233-239.
28. Geldmacher DS, Frolich L, Doody RS, Erkinjuntti T, Vellas B, Jones RW, BanerjeeS, Lin P, Sano M. 2006. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging 10: 417-429.
29. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G. 2011. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol 68: 45-50.
30. Gelinas I, Gauthier L, McIntyre M, Gauthier S. 1999. Development of a functional measure for persons with Alzheimer's disease: The disability assessment for dementia. Am J Occup Ther 53: 471-481.
31. Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamägi Ü, Sawchak S. 2010. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: Results from a randomized, double-blind, placebo-controlled Phase III study. Dement Geriatr Cogn Disord 30: 131-146.
32. Harrington C, Sawchak S, Chiang C, Davies J, Saunders A, Irizarry M, Zvartau-Hind M, van Dyck C, Gold M. 2009. Effects of rosiglitazone-extended release as adjunctive therapy to acetylcholinesterase inhibitors over 48 weeks on cognition in apoe4-stratified subjects with mild-to-moderate Alzheimer's disease. Alzheimers Dement 5: e17-e18.
33. Henderson VW. 2006. Estrogen-containing hormone therapy and Alzheimer's disease risk: Understanding discrepant inferences from observational and experimental research. Neuroscience 138: 1031-1039.
34. Henderson S, Vogel J, Barr L, Garvin F, Jones J, Costantini L. 2009. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: A randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab 6: 31.
35. Herrmann N, Lanctot KL, Rothenburg LS, Eryavec G. 2007. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dement Geriatr Cogn Disord 23: 116-119.
36. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, Pandita-Gunawardena ND, Hogg F, Clare C, Damms J. 2004. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 63: 214-219.
37. Jack CR Jr., Petersen RC, Grundman M, Jin S, Gamst A, Ward CP, Sencakova D, Doody RS, Thal LJ. 2008. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging 29: 1285-1295.
38. Jelic V, Kivipelto M, Winblad B. 2006. Clinical trials in mild cognitive impairment: Lessons for the future. J Neurol Neurosurg Psychiatry 77: 429-438.
39. Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, Tangalos EG, BoeveBF, Knopman DS, Braak H, et al. 2006. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 63: 674-681.
40. Jones R. 2010. Dimebon disappointment. Alzheimers Res Ther 2: 25.
41. Kales HC, Valenstein M, Kim HM, McCarthy JF, Ganoczy D, Cunningham F, Blow FC. 2007. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 164: 1568-1576.
42. Kavirajan H, Schneider LS. 2007. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A meta-analysis of randomised controlled trials [see comment]. Lancet Neurol 6: 782-792.
43. Kimura M, Akasofu S, Ogura H, Sawada K. 2005. Protective effect of donepezil against Aβ (1-40) neurotoxicity in rat septal neurons. Brain Res 1047: 72-84.
44. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, PerdomoC, Ieni JR, Rogers S. 2003. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 160: 2003-2011.
45. Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, Klunk W, Dekosky ST. 2009. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80: 600-607.
46. Lyketsos CG, Sheppard JM, Steele CD, Kopunek S, Steinberg M, Baker AS, Brandt J, Rabins PV. 2000. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: Initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry 157: 1686-1689.
47. Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M. 2007. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68: 1800-1808.
48. Martinez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Rammes G, Parsons CG, Gupta S, Banerjee P, LaFerla FM. 2010. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol 176: 870-880.
49. McCarney R, Fisher P, Iliffe S, van Haselen R, Griffin M, van der Meulen J, Warner J. 2008. Ginkgo biloba for mild to moderate dementia in a community setting: A pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry 23: 1222-1230.
50. McGuinness B, Craig D, Bullock R, Passmore P. 2009. Statins for the prevention of dementia. Cochrane Database Syst Rev CD003160.
51. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. 2000. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet 356: 2031-2036.
52. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, et al. 2000. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study. J Am Med Assoc 283: 1007-1015.
53. Okamura N, Funaki Y, Tashiro M, Kato M, Ishikawa Y, Maruyama M, IshikawaH, Meguro K, Iwata R, Yanai K. 2008. In vivo visualization of donepezil binding in the brain of patients with Alzheimer's disease. Br J Clin Pharmacol 65: 472-479.
54. Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD. 2002. Provisional diagnostic criteria for depression of Alzheimer disease: Rationale and background. Am J Geriatr Psychiatry 10: 129-141.
55. Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S. 2006. Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14: 704-715.
56. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B. 2001. Current concepts in mild cognitive impairment. Arch Neurol 58: 1985-1992.
57. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, GalaskoD, Jin S, Kaye J, Levey A, et al. 2005. Vitamin E and donepezil for the treatment of mild cognitive impairment [see comment]. New Engl J Med 352: 2379-2388.
58. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. 2008. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: A randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5: 83-89.
59. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr., Weiner M, et al. 2010. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial. J Am Med Assoc 304: 1903-1911.
60. Rafii MS, Walsh S, Little JT, Behan KE, Reynolds B, Ward CJ, Thomas R, Aisen PS. 2011. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 76: 1389-1394.
61. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. 2003a. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348: 1333-1341.
62. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, Memantine Study Group. 2003b. Memantine in moderate-to-severe Alzheimer's disease [see comment]. New Engl J Med 348: 1333-1341.
63. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. 2005. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2: 131-136.
64. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD. 2006. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6: 246-254.
65. Rosen WG, Mohs RC, Davis KL. 1984. A new rating scale for Alzheimer's disease. Am J Psychiatry 141: 1356-1364.
66. Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, et al. 2010. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry 18: 136-145.
67. Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. 2009. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther 1: 7.
68. Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D. 2010. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord 25: 206-212.
69. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, et al. 1997. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study [see comment]. New Engl J Med 336: 1216-1222.
70. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. 2011. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32: 1626-1633.
71. Scheltens P, Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Wurtman RJ, Wilkinson D, Twisk JWR, Kurz A. 2010. Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. Alzheimers Dement 6: 1-10; e11.
72. Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, Ferris SH, Mackell JA, Schafer K, Thal LJ. 1997. The severe impairment battery: Concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 (Suppl 2): S51-S56.
73. Schneider LS. 2008a. Ginkgo biloba extract and preventing Alzheimer disease [comment]. J Am Med Assoc 300: 2306-2308.
74. Schneider LS. 2008b. Issues in design and conduct of clinical trials for cognitive-enhancing drugs. In Animal and translational models for CNS drug discovery (ed. Robert AM, Franco B), pp. 21-76. Academic, San Diego.
75. Schneider LS, Sano M. 2009. Current Alzheimer's disease clinical trials: Methods and placebo outcomes. Alzheimers Dement 5: 388-397.
76. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH. 1997. Validity and reliability of the Alzheimer's Disease Cooperative Study-clinical global impression of change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 (Suppl 2): S22-S32.
77. Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M. 2005. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type [see comment]. Curr Alzheimer Res 2: 541-551.
78. Schneider LS, Dagerman K, Insel PS. 2006. Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14: 191-210.
79. Schneider LS, Insel PS, Weiner MW, for the Alzheimer's Disease Neuroimaging Initiative. 2011. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol 68: 58-66.
80. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd., Assaf AR, Jackson RD, et al. 2003. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. J Am Med Assoc 289: 2651-2662.
81. Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley KM, Jacoby R, Refsum H. 2010. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: A randomized controlled trial. PLoS One 5: e12244.
82. Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, Irvine C. 1998. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 155: 54-61.
83. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. 2004. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. J Am Med Assoc 291: 317-324.
84. Tariot PN, Raman R, Jakimovich L, Schneider L, Porsteinsson A, Thomas R, Mintzer J, Brenner R, Schafer K, Thal L. 2005. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: A randomized, controlled trial. Am J Geriatr Psychiatry 13: 942-949.
85. Trompet S, van Vliet P, de Craen AJ, Jolles J, Buckley BM, Murphy MB, Ford I, Macfarlane PW, Sattar N, Packard CJ, et al. 2010. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 257: 85-90.
86. Tuszynski MH, Thal L, Pay M, Salmon DP, HS UBakay R, Patel P, Blesch A, Vahlsing HL, Ho G, et al. 2005. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11: 551-555.
87. van Dyck CH, Tariot PN, Meyers B, Resnick ME. 2007. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 21: 136-143.
88. Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ. 2001. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: An 18-month randomised, double-blind, placebo-controlled study. Lancet 358: 455-460.
89. Vingtdeux V, Dreses-Werringloer U, Zhao H, Davies P, Marambaud P. 2008. Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci 9 (Suppl 2): S6.
90. Weintraub D, Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, et al. 2010. Sertraline for the treatment of depression in Alzheimer disease: Week-24 outcomes. Am J Geriatr Psychiatry 18: 332-340.
91. Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG. 2004. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: A meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry 19: 624-633.
92. Wimo A, Winblad B. 2003. Resource utilisation in dementia: RUD Lite. Brain Aging 3: 48-59.
93. Winblad B, Poritis N. 1999. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 14: 135-146.
94. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, WetterholmAL, Zhang R, Haglund A, Subbiah P. 2001. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57: 489-495.